Another ADC targeting Trop2, Datopotamab deruxtecan (Datopotamab-DXd), was found to cause predominantly non-haematologic adverse events in 33% of patients, with grade 3 or higher events occurring most commonly as stomatitis (13%) (Tarantino et al, 2021). Here, TACSTD2 is linked to stomatitis.